Researchers at the University of Southern California (USC) are at the forefront of Alzheimer’s disease research, employing cutting-edge artificial intelligence (AI) and advanced computing technologies to enhance understanding and treatment of the disease. Paul Thompson, a professor at the Keck School of Medicine, highlights the limitations of traditional genome sequencing and the potential of AI-driven genomic language models to identify complex genetic patterns associated with Alzheimer’s. The ENIGMA Consortium, which Thompson directs, is leveraging AI to tackle significant challenges in Alzheimer’s research, aiming for earlier diagnoses and novel treatment options.

AI is also revolutionizing how researchers interpret advanced imaging data, allowing for the detection of subtle brain changes that may indicate Alzheimer’s. Associate Professor Andrei Irimia has developed a deep neural network that predicts biological brain aging from MRI scans with up to 91% accuracy. Additionally, USC is exploring speech patterns as potential biomarkers for Alzheimer’s, with University Professor Shrikanth Narayanan leading a project that uses AI to analyze natural speech activity.

In drug discovery, USC researchers are utilizing a computational platform called V-SYNTHES to expedite the identification of effective compounds for Alzheimer’s treatment. This platform can predict viable drug candidates from trillions of possibilities, significantly reducing the time needed for drug development. Furthermore, Dong Song is working on an implantable brain-machine interface designed to enhance memory recall in Alzheimer’s patients, showcasing the potential of AI in clinical applications. Overall, USC's innovative approaches are paving the way for breakthroughs in understanding and treating Alzheimer’s disease.